Beam Therapeutics (BEAM) grants CMO 88,500 stock options at $27.62

Rhea-AI Filing Summary

Beam Therapeutics Inc. reported that its Chief Medical Officer, Simon Amy, received a new stock option grant. On January 31, 2026, Simon Amy was awarded a stock option to buy 88,500 shares of Beam common stock at an exercise price of $27.62 per share, expiring on January 31, 2036. The option was granted at no cost to receive it and will vest in equal monthly installments over 48 months, contingent on continued service with Beam Therapeutics through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simon Amy

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	88,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 88,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Amy

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.

238 MAIN STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.62	01/31/2026		A		88,500		(1)	01/31/2036	Common Stock	88,500	$0.00	88,500	D

Explanation of Responses:

1. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Beam Therapeutics (BEAM) disclose for Simon Amy?

Beam Therapeutics disclosed that Chief Medical Officer Simon Amy received a stock option grant for 88,500 shares on January 31, 2026. The option allows purchase of Beam common stock at an exercise price of $27.62 per share, expiring on January 31, 2036.

What are the key terms of the 88,500-share stock option granted by Beam (BEAM)?

The grant is a stock option (right to buy) covering 88,500 shares of Beam common stock at an exercise price of $27.62 per share. It expires on January 31, 2036, with the option initially received for $0.00 in derivative purchase price.

How does the Beam Therapeutics (BEAM) stock option for Simon Amy vest?

The stock option vests in equal monthly installments over 48 months following the grant date. Each monthly vesting is conditioned on Simon Amy continuing to serve with Beam Therapeutics Inc. through the applicable vesting date, aligning vesting with ongoing employment.

What is the ownership status of the new Beam (BEAM) stock option reported?

After the reported transaction, 88,500 derivative securities (stock options) are beneficially owned on a direct basis. The Form 4 lists the ownership form as Direct (D), with no indication of indirect holding entities or disclaimers of beneficial ownership in the provided footnote.

Does the Beam Therapeutics (BEAM) Form 4 show any stock sales by Simon Amy?

The Form 4 shows an acquisition of a derivative security, not a sale of common shares. It reports a grant of stock options coded as transaction type A (acquired), with 88,500 options awarded and no listed dispositions of Beam common stock.

What role does Simon Amy hold at Beam Therapeutics (BEAM) in this filing?

In this filing, Simon Amy is identified as an officer of Beam Therapeutics Inc., serving as Chief Medical Officer. The relationship box marks Simon Amy as an officer but not a director and not a ten percent owner based on the provided information.